Paraganglioma Companies

Roche Holding AG Received FDA approval for Hemlibra (emicizumab) for the treatment of spinal cord compression related to bone metastases in solid tumors, potentially benefiting paraganglioma patients with spinal involvement.Conducted research on combining Hemlibra with radiotherapy for synergistic effects in controlling paraganglioma progression and preventing new tumor formation.

Novartis AG Presented positive preliminary data from a Phase II clinical trial investigating their radiopharmaceutical therapy Lutathera (Lu-177 dotatate) for treating castration-resistant prostate cancer with paraganglioma metastases, showcasing potential for improved pain management and survival outcomes.Expanded their research efforts on CAR-T cell therapy specifically targeting mutations commonly found in paragangliomas, aiming for a personalized and potentially curative treatment approach.

Eusa Pharma Launched their next-generation MIBG scintigraphy imaging agent, Iobenguane I-123, offering improved tumor visualization and potentially guiding more precise surgical or radiotherapeutic interventions.Partnered with patient advocacy groups to raise awareness about paragangliomas and provide educational resources for patients and their families.

MD Anderson Cancer Center Developed a new genetic sequencing panel specifically for paragangliomas, providing detailed information on tumor mutations and aiding in personalized treatment decisions.Conducted clinical trials evaluating novel targeted therapies and combination regimens for different paraganglioma subtypes, pushing the boundaries of treatment options.

Paraganglioma Foundation International Launched a fundraising campaign to support research on paraganglioma genetics, diagnostics, and new treatment modalities.Organized patient conferences and support groups to connect individuals with paragangliomas, share experiences, and provide access to medical and emotional support.

List of Paraganglioma Key Companies in the Market

• Bristol-Myers Squibb Company (U.S.)


• GlaxoSmithKline Plc. (U.K.)


• Bayer AG (Germany)


• Novartis AG (Switzerland)


• Spectrum Pharmaceuticals Inc. (U.S.)


• Amgen, Inc. (U.S.)


• Eli Lilly and Company (U.S.)


• AstraZeneca Plc. (U.K.)


• F. Hoffmann-La Roche Ltd. (Switzerland)


• Janssen Biotech, Inc. (U.S.)


• AbbVie Inc. (U.S.)


• Takeda Pharmaceuticals (Japan)


• Pfizer, Inc. (U.S.)


• Sanofi (France)


• Merck & Co., Inc. (U.S.)


• Immunomedics (U.S.)


• Oncomed Pharmaceuticals (U.S.)